Abbott (ABT Quick QuoteABT - Free Report) reported $13.01 billion in revenue for the quarter ended September 2026, representing a year-over-year increase of 14.5%. EPS of $1.42 for the same period compares to $1.30 a year ago.

The reported revenue represents a surprise of +0.3% over the Zacks Consensus Estimate of $12.97 billion. With the consensus EPS estimate being $1.43, the EPS surprise was -0.7%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Abbott performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales- Nutrition- U.S.: $958 million compared to the $931.65 million average estimate based on four analysts. The reported number represents a change of +7.9% year over year.
• Net sales- Nutrition- International: $1.3 billion versus $1.28 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.1% change.
• Net sales- Diagnostics- U.S.: $1.85 billion versus the four-analyst average estimate of $1.85 billion. The reported number represents a year-over-year change of +109.1%.
• Net sales- Diagnostics- International: $1.45 billion versus the four-analyst average estimate of $1.44 billion. The reported number represents a year-over-year change of +6.2%.
• Net sales- Nutrition: $2.26 billion versus the five-analyst average estimate of $2.21 billion. The reported number represents a year-over-year change of +5.1%.
• Net sales- Diagnostics: $3.31 billion versus $3.29 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +46.7% change.
• Net sales- Medical Devices- Diabetes Care: $2.19 billion compared to the $2.2 billion average estimate based on five analysts. The reported number represents a change of +6.2% year over year.
• Net sales- Established Pharmaceuticals: $1.61 billion versus the five-analyst average estimate of $1.61 billion. The reported number represents a year-over-year change of +6.8%.
• Net sales- Medical Devices- Vascular- Total: $786 million versus $775.46 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.5% change.
• Net sales- Medical Devices- Neuromodulation- Total: $251 million versus the four-analyst average estimate of $263.09 million. The reported number represents a year-over-year change of -1.2%.
• Net sales- Medical Devices- Structural Heart- Total: $592 million compared to the $598.89 million average estimate based on four analysts. The reported number represents a change of -6.8% year over year.
• Net sales- Medical Devices- Heart Failure- Total: $387 million versus $396.07 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.7% change.

View all Key Company Metrics for Abbott here>>>

Shares of Abbott have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.